Last reviewed · How we verify
NCT02090530
Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
Recruiting now
Last updated 8 April 2026
What this trial tests
trial testing Biospecimen collection in Cancer in 1,000 participants. Currently enrolling.
Timeline
4 November 2013
Primary endpoint
31 December 2027
31 December 2027
31 December 2027
Quick facts
| Lead sponsor | Ohio State University Comprehensive Cancer Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 4 November 2013 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Biospecimen collection — full drug profile →
Conditions studied
- Cancer — all drugs for Cancer →
Sponsor
Ohio State University Comprehensive Cancer Center
Who can join
18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.
Krook MA, Lenyo A, Wilberding M, Barker H, et al · · 2020 · cited 117× · PMID 31911531 · DOI 10.1158/1535-7163.mct-19-0631 -
Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy.
Krook MA, Bonneville R, Chen HZ, Reeser JW, et al · · 2019 · cited 66× · PMID 31371345 · DOI 10.1101/mcs.a004002 -
Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy.
Chen HZ, Bonneville R, Paruchuri A, Reeser JW, et al · · 2021 · cited 14× · PMID 34590014 · DOI 10.1016/j.jtocrr.2021.100164 -
FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer.
Stein L, Murugesan K, Reeser JW, Risch Z, et al · · 2024 · cited 8× · PMID 39289482 · DOI 10.1038/s41698-024-00683-x -
Characterization of Clonal Evolution in Microsatellite Unstable Metastatic Cancers through Multiregional Tumor Sequencing.
Bonneville R, Paruchuri A, Wing MR, Krook MA, et al · · 2021 · cited 7× · PMID 33229401 · DOI 10.1158/1541-7786.mcr-19-0955 -
Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer.
Wing MR, Reeser JW, Smith AM, Reeder M, et al · · 2017 · cited 7× · PMID 29100271 · DOI 10.18632/oncotarget.20616 -
Growth factor receptor plasticity drives therapeutic persistence of metastatic breast cancer.
Ayers M, Monteiro M, Kulkarni A, Reeser JW, et al · · 2025 · cited 2× · PMID 40185706 · DOI 10.1038/s41419-025-07591-3 -
Myeloid neoplasm with histiocytosis and spleen tyrosine kinase fusion responds to fostamatinib.
Risch Z, Kaffenberger BH, Chung CG, Samorodnitsky E, et al · · 2024 · cited 1× · PMID 38813710 · DOI 10.3324/haematol.2024.285146
Verify or expand the search:
- PubMed search for NCT02090530
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biospecimen collection
Trials testing the same drug.
- NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting
- NCT07157683 — Biomarkers in Systemic Histiocytosis · not yet recruiting
- NCT07058064 — WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring) · NA · recruiting
- NCT06054295 — Somatic Mosaicism in Twins Discordant for Childhood Cancer · recruiting
- NCT06339606 — Pregnancy Repository · not yet recruiting
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other Ohio State University Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT06816979 — Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell · NA · not yet recruiting
- NCT07529483 — Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cysts · Phase 2 · not yet recruiting
- NCT07455513 — A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer · NA · not yet recruiting
- NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting
- NCT07503925 — THRIVE Study: Understanding How Oral Nicotine Pouches Affect Public Health · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT02090530 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center
- Last refreshed: 8 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02090530.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing